Unlock instant, AI-driven research and patent intelligence for your innovation.

Modified adenovirus vectors for use in vaccines and gene therapy

A technology of viral vector, adenovirus, used in immunization, medical field

Inactive Publication Date: 2005-09-14
JANSSEN VACCINES & PREVENTION BV
View PDF10 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In contrast, inoculation of mice with a mutant LCMV strain called 'clone 3' (which differs by 2 amino acids from the parental strain) resulted in persistent infection and marked immunosuppression

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modified adenovirus vectors for use in vaccines and gene therapy
  • Modified adenovirus vectors for use in vaccines and gene therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1. Protection of mature dendritic cells from CTL-mediated lysis

[0047] First, experiments were performed to replicate the findings of others: immature dendritic cells are sensitive to CTL-mediated killing whereas mature dendritic cells are protected. For this, blood was isolated from a healthy adult individual and subsequently used to isolate peripheral blood mononuclear cells by the ficoll procedure. Monocytes were isolated from the cell population using the Variomacs technique and CD14-specific antibodies (Miltenyi Biotec GmbH) known to those skilled in the art. These monocytes were cultured for 6 days in the presence of 100 ng / ml IL-4 (Bioscource International, Inc.) and 800 IU / ml GM-CSF (Leucomax; Novartis) to obtain immature dendritic cells. Correct differentiation of monocytes to immature dendritic cells was monitored by FACScalibur measuring cell surface expression with antibodies (from BD Pharmingen). As known to those of ordinary skill in the art of...

Embodiment 2

[0052] Example 2. Adenovirus-mediated induction of sensitized mature dendritic cells

[0053] As described above, the procedures for obtaining mature and immature dendritic cells from human peripheral blood mononuclear cells, loading the cells with europium, and loading the gp100 peptide have been roughly described. Dendritic cells were incubated with the replication-deficient adenoviral vector for 48 hours (1000 of the virus particles per cell (vp / cell)). Control groups were not incubated with adenoviral vector. The adenovirus vector used was based on adenovirus serotype 5 (Ad5), but deleted the entire adenovirus El region. In addition, the vector used was genetically engineered to carry a fiber molecule from adenovirus serotype 35, giving it a better tropism for dendritic cells. WO 00 / 03029 and WO 02 / 24730 describe in detail how to generate Ad5 viruses carrying fibers from various (other) serotypes. The vector contains a eukaryotic expression cassette in the E1 region con...

Embodiment 3

[0056] Example 3. Regulation of sensitization of mature dendritic cells by recombinant adenovirus

[0057] It has been documented that upregulation of SPI-6 in mice or PI-9 in humans or keeping their levels stable is at least partly involved in biological pathways by which mature dendritic cells resist CTL-mediated killing. To investigate whether adenovirus sensitizes dendritic cells through the PI-9 pathway, two different experimental strategies were performed: (i) Western blot analysis and / or reverse transcription PCR to determine whether adenovirus was or was not exposed to adenovirus Expression levels of PI-9 protein and / or RNA in human dendritic cells of the vector. (ii) Generation of adenoviral vector carrying PI-9 cDNA followed by infection of mature and immature dendritic cells to determine the effect of PI-9 overexpression on CTL-mediated killing.

[0058] To determine expression levels of PI-9, mature and immature dendritic cells from human monocytes were obtained a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides novel methods and means for influencing the CTL-sensitivity of antigen presenting cells (such as dendritic cells) upon viral infections. The invention provides gene delivery vehicles useful in different therapeutic settings such as vaccination and / or gene therapy.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the field of immunization using the improved adenovirus vector. The invention also relates to the field of gene therapy and methods and means for altering the immune response in patients treated with viral vectors carrying transgenes, such as adenoviruses. Background technique [0002] Examples of existing vaccines include live attenuated vaccines, whole inactivated vaccines, subunit vaccines (whether based on recombinant proteins or not), peptide vaccines, (naked) DNA vaccines, and immunogenic vectors such as modified vaccinia virus (MVA ), recombinant adenoviruses, poxviruses, or alphaviruses. Since for many diseases it is not known which component of the immune system (antibodies and / or T cells) is responsible for protection, an ideal vaccine should elicit both a potent cellular and humoral response. Adenoviruses are valued in the art because of their ability to be prepared in high t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/57A61K39/00A61K48/00C12N5/0781C12N5/0784C12N5/22C12N15/86C12N15/861
CPCC12N2810/6018A61K2039/5256A61K48/00C12N2710/10343A61K38/57C12N5/0635C12N5/0639C12N15/86A61P7/06A61P9/10A61P19/02A61P35/00A61P37/00A61P43/00
Inventor 斯特凡·科斯滕斯奥尔佳·约翰娜·阿伯丁娜·埃莉萨·奥霍斯特曼佐·扬斯·埃姆柯·哈文加
Owner JANSSEN VACCINES & PREVENTION BV